Methods for testing the risk of developing cardiovascular events

The method addresses the complexity and inaccuracy of existing cardiovascular event prediction by employing platelet count and CD40L trends, facilitating easy and accurate risk assessment in general medical settings.

JP7584125B2Active Publication Date: 2024-11-15CHIBA UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2020183779
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-11-02
Publication Date
2024-11-15
Estimated Expiration
2040-11-02

AI Technical Summary

Technical Problem

Current methods for predicting cardiovascular events, such as stroke and myocardial infarction, lack accuracy and are too complex for widespread implementation in general medical facilities, making it difficult to identify prognostic factors effectively.

Method used

A method using fluctuation trends in platelet count and CD40 ligand (CD40L) concentration in blood samples to determine the risk of cardiovascular events, involving simple sample collection, centrifugation, and plotting platelet data, with CD40L quantification via ELISA, enabling easy and accurate risk assessment.

Benefits of technology

Enables rapid, cost-effective risk assessment of cardiovascular events with high sensitivity and specificity, particularly beneficial for chronic dialysis patients, by utilizing commonly available testing methods and kits.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007584125000002
    Figure 0007584125000002
  • Figure 0007584125000003
    Figure 0007584125000003
  • Figure 0007584125000004
    Figure 0007584125000004
Patent Text Reader

Abstract

To provide a method capable of easily determining the onset risk of a cardiovascular event with high accuracy.SOLUTION: Disclosed is a method for determining the onset risk of a cardiovascular event in an analyte. This method includes the steps of (a) acquiring a value of the platelet number in a plurality of blood samples collected from the analyte at a plurality of time points; and (b) determining that the onset risk of the cardiovascular event is high when the decreasing tendency of the platelet number is observed and determining that the onset risk of the cardiovascular event is low when the increasing tendency of the platelet number is observed.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for examining the risk of developing a cardiovascular event. [Background technology]

[0002] In recent years, with the westernization of lifestyle habits, the number of cases of arteriosclerosis has been rapidly increasing in Japan. In recent preventive medicine, the focus is on correcting risk factors for arteriosclerosis, such as hypertension and hyperlipidemia. Unfortunately, however, cardiovascular disease has now become the leading cause of death in Japan. One of the reasons for this is the lack of accurate predictive markers for the onset of cardiovascular events, such as stroke and acute myocardial infarction. The various pathologies that arise as a result of the progression of arteriosclerotic lesions not only significantly reduce the patient's quality of life, but also cause enormous social losses. There is an increasing need to suppress the onset of cardiovascular disease events, and in that sense, the significance of identifying prognostic predictors is extremely great.

[0003] As such prognostic predictors, Non-Patent Documents 1 and 2 report that the measured values ​​of platelet count and platelet aggregation ability are associated with the onset of stroke and myocardial infarction.

[0004] However, although the conventional methods described above require measurements to be taken immediately after sample collection, the testing techniques and procedures are extremely cumbersome, making them difficult to implement in general medical facilities and screening sites, and the prediction accuracy is low, so there is still room for improvement. [Prior art documents] [Non-patent literature]

[0005] [Non-Patent Document 1] Sharp DS, et.al. Platelet aggregation in whole blood is a paradoxical predictor of ischaemic stroke: Caerphilly Prospective Study revisited. Platelets. 2005; 16: 320-8 [Non-Patent Document 2] Thaulow E, et.al. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation. 1991; 84: 613-7 Summary of the Invention

[0006] The present inventors have found that the risk of developing a cardiovascular event can be determined simply and with high accuracy by using the trend of fluctuations in the blood platelet count as an index. Furthermore, the present inventors have found that the accuracy of determining the risk of developing a cardiovascular event can be further improved by using the concentration of CD40 ligand (CD40L) in a blood sample as an index in addition to the trend of fluctuations in the platelet count. The present invention is based on these findings.

[0007] Therefore, the present invention provides a method capable of determining the risk of developing a cardiovascular event simply and with high accuracy.

[0008] The present invention includes the following inventions. (1) A method for determining a risk of developing a cardiovascular event in a subject, comprising: (a) obtaining platelet count values ​​in multiple blood samples taken from the subject at multiple time points; and (b) determining that the risk of developing a cardiovascular event is high when a tendency for the platelet count to decrease is observed, and determining that the risk of developing a cardiovascular event is low when a tendency for the platelet count to increase is observed. The method comprising: (2) The method according to (1) above, in step (b), the platelet count values ​​obtained in step (a) are plotted against a time axis, and when an inflection point is observed, the platelet count values ​​are plotted from the most recent inflection point to the most recent plot, and when no inflection point is observed, the platelet count values ​​are plotted from the oldest plot to the most recent plot. If a decreasing trend is observed, the risk of developing a cardiovascular event is determined to be high, and if an increasing trend is observed, the risk of developing a cardiovascular event is determined to be low. (3) A method for determining a risk of developing a cardiovascular event in a subject, comprising: (i) obtaining platelet count values ​​in multiple blood samples taken from the subject at multiple time points; (ii) obtaining a quantitative value of CD40 ligand (CD40L) in at least one of a plurality of blood samples taken from the subject at a plurality of time points; and (iii) determining that the individual is at high risk of developing a cardiovascular event if the platelet count shows a tendency to decrease and the value obtained by dividing the CD40L quantitative value by the platelet count in a blood sample collected at the same time point as the blood sample used for the quantification is lower than the value for an individual at low risk of developing a cardiovascular event. The method comprising: (4) The method according to (3) above, wherein in step (iii), the platelet count values ​​obtained in step (i) are plotted against a time axis, and when an inflection point is observed, a decreasing trend is observed from the most recent inflection point to the most recent plot, or when no inflection point is observed, from the oldest plot to the most recent plot, and when the value obtained by dividing the quantitative CD40L value by the platelet count value in a blood sample collected at the same time point as the blood sample used for the quantification is lower than the value for an individual at low risk of developing a cardiovascular event, the individual is determined to be at high risk of developing a cardiovascular event. (5) The method according to any one of (1) to (4) above, wherein the subject is a human. (6) The method according to (5) above, wherein the subject is a human after developing critical limb ischemia. (7) The method according to (5) above, wherein the subject is a chronic maintenance dialysis patient.

[0009] In the method of the present invention, the work in the medical field can be limited to the work of collecting, centrifuging, and freezing and storing plasma samples as shown in FIG. 2, and the work of plotting blood data as shown in FIG. 1, so that the method is easier to implement than the conventional technology. In addition, the quantification of CD40 ligand (CD40L) in the plasma sample is performed by the ELISA method, which is a technique commonly used by general testing contract companies, or can be performed by simply introducing a CD40L measurement kit that is widely available on the market, so that the method can be performed at low cost. In particular, the present invention is advantageous in that it can determine the risk of imminent onset within a short period (e.g., 6 months) after the test. Furthermore, the present invention is considered to be significantly superior in chronic maintenance dialysis patients (who are regularly tested for blood tests) who have a high incidence of cardiovascular events. [Brief description of the drawings]

[0010] [Figure 1] Figure 1 is a graph in which the platelet count in blood collected from a subject at multiple time points is plotted against the time axis. In Figure 1, the moving average (7-day moving average) of the platelet count measurements is plotted against the time axis, and the most recent inflection point is identified retroactively from the date of visit. The platelet count (moving average) at the inflection point is defined as σ (baseline), the difference obtained by subtracting the platelet count (moving average) at the inflection point from the platelet count (moving average) on the date of visit is defined as δ, and δ / σ×100 is defined as the platelet count fluctuation value (%). [Diagram 2] FIG. 2 is a diagram showing an example of a procedure for processing a blood sample after blood is collected from a subject. [Diagram 3] Figure 3 is a graph plotting the platelet count fluctuation value (%) on the horizontal axis and [CD40L quantitative value (ng / μL)] / [platelet count ( / μL)] on the day of consultation on the vertical axis. In Figure 3, the dark plots represent samples from patients who developed cardiovascular events within 6 months from the day of consultation. [Figure 4]Figure 4 is a graph plotting the platelet count fluctuation value (%) on the horizontal axis and [CD40L quantitative value (ng / μL)] / [platelet count ( / μL)] on the day of consultation on the vertical axis. In Figure 4, the dark plots (plots with arrows in the enlarged view on the right) are samples from patients who developed cardiovascular events within 6 months from the day of consultation. Description of the Invention

[0011] The method of the first aspect of the present invention includes a step of obtaining platelet count values ​​in a plurality of blood samples taken from a subject at a plurality of time points, and determining that the risk of developing a cardiovascular event is high when the platelet count tends to decrease, and determining that the risk of developing a cardiovascular event is low when the platelet count tends to increase.

[0012] The method of the second aspect of the present invention includes the steps of (i) obtaining platelet count values ​​in a plurality of blood samples taken from a subject at a plurality of time points, and (ii) obtaining a quantitative value of CD40 ligand (CD40L) in at least one of the plurality of blood samples taken from the subject at a plurality of time points. In this method, if a tendency for a decrease in platelet count is observed and the value obtained by dividing the quantitative value of CD40L by the platelet count value in a blood sample taken at the same time point as the blood sample used for the quantification is lower than the value for an individual at low risk of developing a cardiovascular event, the individual is determined to be at high risk of developing a cardiovascular event.

[0013] In this specification, the term "cardiovascular event" refers to the occurrence of symptoms in cardiovascular disease, and specifically includes, for example, cardiovascular death (fatal myocardial infarction, nonfatal stroke, sudden cardiac death), nonfatal myocardial infarction, nonfatal stroke, percutaneous coronary intervention (PCI), AC bypass surgery, other cardiovascular reconstruction surgery, new onset of rest angina and exertion angina, destabilization of angina (hospitalization, PCI, AC bypass surgery, other cardiovascular reconstruction surgery), etc. According to a preferred embodiment of the present invention, the cardiovascular event is sudden cardiac death, acute myocardial infarction, unstable angina, ischemic stroke, transient ischemic attack, or acute arterial occlusion (including after bypass surgery and after dialysis shunt surgery).

[0014] In the present specification, the "subject" is not particularly limited as long as it is an animal that may develop a cardiovascular event, and specifically includes humans, monkeys, rodents such as rats, etc., and is preferably humans. The method of the present invention is particularly preferably performed on humans suspected of having arteriosclerotic disease, humans after developing critical limb ischemia (CLI) or arteriosclerotic disease, or patients undergoing chronic maintenance dialysis.

[0015] The blood sample used in the method of the present invention is preferably taken from the subject immediately after measurement, but may be stored. There is no particular limitation on the method of storing the blood sample as long as the amount of platelets in the sample does not change. For example, it is preferable to store the blood sample under low temperature conditions of 0 to 10°C without freezing, in a dark place, and without vibration.

[0016] The "blood sample" for measuring the platelet count is not particularly limited as long as it contains platelets and the number (concentration) can be measured, but a whole blood sample is usually used. As the whole blood sample, blood (whole blood) collected from a subject may be used as is, or additives such as EDTA potassium salt or heparin may be added for the purpose of preventing coagulation, etc. The timing of blood collection to collect the blood sample from the subject is not particularly limited.

[0017] There is no particular limitation on the method for measuring the amount of platelets in a blood sample, and a conventionally known method can be appropriately adopted. In particular, the measurement of the platelet count is a major test item that is also adopted in blood tests in general health checkups, and a great deal of knowledge exists about techniques for measuring the amount of platelets in a blood sample.

[0018] In the method of the present invention, the platelet count fluctuation is used as an index for judgment. The platelet count fluctuation can be examined by measuring the platelet count in blood samples from each subject at multiple time points, plotting the obtained measured values ​​on a graph, and observing the change over time. Here, the measured values ​​plotted on the graph are preferably moving average values ​​(e.g., 3-day moving average value, 5-day moving average value, 7-day moving average value, or 7-day or more moving average value). More specifically, as illustrated in FIG. 1, the moving average value (7 days or more) of the measured platelet count is plotted against the time axis, and the most recent inflection point is identified retroactively from the most recent blood collection time, the platelet count (moving average value) at the inflection point is set as σ (baseline), the difference obtained by subtracting the platelet count (moving average value) at the inflection point from the platelet count (moving average value) at the most recent blood collection is set as δ, and δ / σ×100 can be set as the platelet count fluctuation value (%). If this platelet count fluctuation value (%) is smaller than 0, a tendency for the platelet count to decrease is indicated, and if it is larger than 0, a tendency for the platelet count to increase is indicated. In addition, when there is no inflection point, the platelet count (moving average value) at the earliest blood sampling is set as σ (baseline), and the difference obtained by subtracting σ from the platelet count (moving average value) at the latest blood sampling is set as δ. The period from the inflection point or the earliest blood sampling to the latest blood sampling is not particularly limited, but is preferably 7 days or more. The number of blood samples obtained from the inflection point or the earliest blood sampling to the latest blood sampling is not particularly limited, but is preferably 5 or more.

[0019] There are no particular limitations on the "blood sample" for measuring CD40L, so long as it contains CD40L and its number (concentration) can be measured, but preferably serum or plasma (platelet poor plasma, platelet free plasma) is used, more preferably plasma (platelet poor plasma, platelet free plasma), and even more preferably plasma centrifuged within 30 minutes after blood collection. Such blood samples can be prepared, for example, by collecting, centrifuging, and freezing and storing a plasma sample as shown in Figure 2. In particular, the use of a frozen and stored blood sample (e.g., plasma) is particularly preferred, as this facilitates centralization of analysis.

[0020] There is no particular limitation on the method for measuring the concentration of CD40L in a blood sample, and any conventionally known method can be appropriately adopted. Many such methods are known, and kits for carrying out such methods are also commercially available.

[0021] In the method of the second aspect of the present invention, when the value obtained by dividing the quantitative value of CD40L by the platelet count in a blood sample collected at the same time point as the blood sample used for the quantification is used as an index, the value is compared with the value for an individual at low risk of developing a cardiovascular event. For such comparison, the value measured for a low-risk individual may be used each time, or an appropriate cut-off value may be defined based on the value for a low-risk individual and used for comparison. The CD40L concentration in a blood sample from a low-risk individual can be obtained by collecting blood from an individual who has been clinically confirmed in advance not to be in the high-risk group for developing a cardiovascular event, and subjecting the blood to the same processing and measurement as for blood collected from a subject for quantification.

[0022] In addition, the plasma CD40L concentration may vary depending on the disease that the individual suffers from. For example, it is known that plasma CD40L concentration is high in individuals suffering from acute myocardial infarction, unstable angina, chronic atrial fibrillation, or diabetes, and is about 5 times higher in acute diseases (acute myocardial infarction and unstable angina), and about 2 times higher in chronic diseases (chronic atrial fibrillation and diabetes). Therefore, when the value obtained by dividing the quantitative value of CD40L by the platelet count in a blood sample collected at the same time point as the blood sample used for the quantification is used as an index, and the value is compared with the value for an individual at low risk of developing a cardiovascular event, it is preferable to consider the variation in plasma CD40L concentration due to such a disease. For example, a cutoff value can be determined for each type of disease that the subject suffers from based on the value of a low-risk individual with the same disease.

[0023] The cutoff value is a value determined when determining whether a substance is a disease group or a non-disease group. When determining whether a substance is a disease group or a non-disease group, a result below the cutoff value is negative, and a result above the cutoff value is positive, or a result below the cutoff value is positive and a result above the cutoff value is negative (Masamitsu Kanai, ed., Summary of Clinical Test Methods, Kanehara Publishing Co., Ltd.).

[0024] Sensitivity and specificity are indices used to evaluate the clinical usefulness of cutoff values. When a population is judged using a cutoff value, and diseased patients who are judged to be positive are represented as a (true positive), diseased patients who are judged to be negative are represented as b (false negative), non-diseased patients who are judged to be positive are represented as c (false positive), and non-diseased patients who are judged to be negative are represented as d (true negative), the value represented by a / (a+b) can be represented as sensitivity (true positive rate), and the value represented by d / (c+d) can be represented as specificity (true negative rate).

[0025] The distribution of measured values ​​between the disease group and the non-disease group of interest usually overlaps partially. Therefore, the sensitivity and specificity change by raising or lowering the cutoff value. Lowering the cutoff value increases the sensitivity but decreases the specificity, and raising the cutoff value decreases the sensitivity but increases the specificity. As a method of determination, it is preferable that both the sensitivity and specificity are high.

[0026] Methods for setting the cutoff value include setting either of the two ends of the median that includes 95% of the distribution of the non-disease group as the cutoff value, or setting the cutoff value to the mean value plus 2 standard deviations (SD) or the mean value minus 2SD when the distribution of the non-disease group shows a normal distribution.

[0027] Generally, in order to determine whether a diagnostic method is useful, since sensitivity and specificity change depending on the cutoff value set as described above, it is more desirable to evaluate using an index that maintains high sensitivity and specificity when the cutoff value is raised or lowered, such as the AUC value of the ROC curve, rather than simply evaluating the sensitivity and specificity at a certain cutoff value. The AUC value of the ROC curve is 1 when there is a cutoff value at which both sensitivity and specificity are 100%, and approaches 0.5 when the diagnostic performance is poor.

[0028] That is, the cutoff value in the method of the present invention can be determined so that any of the above-mentioned sensitivity, specificity, and AUC value of the ROC curve is a preferred value. In addition, the period from the inflection point to the latest blood sampling time when determining the platelet count fluctuation, and the number of blood samples obtained from the inflection point to the latest blood sampling time can also be determined so that any of the above-mentioned sensitivity, specificity, and AUC value of the ROC curve is a preferred value.

[0029] FIG. 3 shows a specific example of selecting a group with a high risk of developing a cardiovascular event from a group with a low risk of developing a cardiovascular event according to the method of the second aspect of the present invention. In this example, a group with a high risk of developing a cardiovascular event is detected with 100% sensitivity based on two criteria: the blood platelet count fluctuation value (%) is smaller than 0, and the plasma CD40L (ng / μL) / platelet count ( / μL) is smaller than 1.00. The specificity is 47%. Without being bound to a particular theory, in the low-risk group, when platelet consumption due to platelet activation is enhanced, the tendency for thrombocytopenia continues, but plasma CD40L shows a high value, so it is thought that cardiovascular events can be avoided if platelet function is normal. On the other hand, in the high-risk group, cardiovascular events cannot be avoided due to the presence of qualitative abnormalities in platelets, and in this case, it is thought that CD40L cannot show a high value.

[0030] In this way, subjects (animals) determined to be at high risk for developing cardiovascular events by the method of the present invention can have a very good prognosis and therapeutic effect by receiving treatment appropriate for each disease. The method of the present invention can also be suitably used for screening of high-risk cases in maintenance blood dialysis, screening of high-risk patients in primary care, screening of high-risk cases in general medical examinations, etc. EXAMPLES

[0031] The present invention will be described in more detail below with reference to examples, but the technical scope of the present invention is not limited to these examples.

[0032] How to measure platelet count and CD40L In the following Examples, the platelet count in blood samples and the CD40 ligand (CD40L) in plasma were measured by the following methods.

[0033] Measuring platelet count Blood samples were collected from subjects and collected in standard EDTA-2K tubes. Various values, including platelet count and mean corpuscular volume (MCV), were then measured using a GEN·S cellular analyzer system (Beckman Coulter) or an XE-2100 Hematology analyzer (Sysmex) according to the manufacturer's instructions. These measuring devices were appropriately calibrated to ensure the accuracy of the measurements.

[0034] Measurement of CD40L CD40L was quantified in plasma samples collected from subjects by ELISA using a commercially available kit (product name: The Quantikine Human CD40 Ligand Immunoassay, R&D Systems Inc.).

[0035] Retrospective cohort study A retrospective cohort study was conducted on 39 patients with critical limb ischemia (CLI) due to arteriosclerosis obliterans (ASO) who underwent mononuclear cell angiogenesis therapy and for whom serum and plasma samples were available before the consultation. In this study, the 39 cases were divided into 7 cases who developed cardiovascular events (CVE) within 6 months of consultation and 32 cases who did not. The cardiovascular events (CVE) actually observed here included sudden death, myocardial infarction, worsening of coronary artery disease, and the onset of cerebrovascular disease.

[0036] The data of the subjects on the days of visit are shown in Table 1 below. [Table 1]

[0037] CD40L in plasma samples from these patients on the day of consultation was quantified, and the platelet count fluctuation up to the day of consultation was examined. The platelet count fluctuation was examined by measuring the platelet count in multiple blood samples from each patient before the day of consultation, plotting the obtained measured values ​​on a graph, and observing the change over time. Specifically, as illustrated in FIG. 1, the moving average (7 days or more) of the platelet count measurements was plotted against the time axis, and the most recent inflection point was identified retroactively from the day of consultation. The platelet count (moving average) at the inflection point was then defined as σ (baseline), and the difference obtained by subtracting the platelet count (moving average) at the inflection point from the platelet count (moving average) on the day of consultation was defined as δ. When no inflection point exists, the platelet count (moving average) at the earliest blood collection was defined as σ (baseline), and the difference obtained by subtracting σ from the platelet count (moving average) at the latest blood collection was defined as δ. δ / σ×100 was defined as the platelet count fluctuation value (%).

[0038] Next, FIG. 4 shows a graph plotting the platelet count fluctuation value (%) on the horizontal axis and [CD40L quantitative value (ng / μL)] / [platelet count ( / μL)] on the day of examination on the vertical axis.

[0039] According to FIG. 4, all samples from patients who developed cardiovascular events showed a platelet count fluctuation value (%) lower than 0%. Furthermore, samples from patients who developed cardiovascular events showed a platelet count fluctuation value (%) lower than 0% and also had a low CD40L quantitative value. Therefore, it was revealed that these indices can determine whether or not a subject has a risk of developing a cardiovascular event in the near future. In particular, in this example, when the cutoff value of the platelet count fluctuation value (%) was 0% and the cutoff value of [CD40L quantitative value (ng / μL)] / [platelet count ( / μL)] was 1.00, the sensitivity as a diagnostic method was 100% and the specificity was 47%.

Claims

1. A method for evaluating a risk of developing a cardiovascular event in a subject in vitro, comprising: (i) obtaining platelet count values ​​in multiple blood samples taken from the subject at multiple time points; (ii) obtaining a quantitative value of CD40 ligand (CD40L) in at least one of a plurality of blood samples taken from the subject at a plurality of time points; and (iii) a step of determining that the risk of developing a cardiovascular event is high when the platelet count shows a tendency to decrease and the value obtained by dividing the CD40L quantification value by the platelet count in a blood sample collected at the same time point as the blood sample used for the quantification is lower than the value for an individual at low risk of developing a cardiovascular event; The method comprising:

2. The method according to claim 1, wherein step (iii) further comprises a step of determining that a tendency for the platelet count to increase is an indication of a low risk of developing a cardiovascular event.

3. 3. The method according to claim 1 or 2, wherein in step (iii), the platelet count values ​​obtained in step (i) are plotted against a time axis, and when an inflection point is observed, a decreasing trend is observed from the most recent inflection point to the most recent plot, or when no inflection point is observed, from the oldest plot to the most recent plot, and the value obtained by dividing the quantitative CD40L value by the platelet count in a blood sample collected at the same time point as the blood sample used for the quantification is lower than the value for an individual at low risk of developing a cardiovascular event, which is an indicator of a high risk of developing a cardiovascular event.

4. The method according to any one of claims 1 to 3, wherein step (iii) further comprises plotting the platelet count values ​​obtained in step (i) against a time axis, and when an inflection point is observed, plotting the platelet count from the most recent inflection point to the most recent plot, or when no inflection point is observed, plotting the platelet count from the oldest plot to the most recent plot, when a trend for an increase is observed, as an indication of a low risk of developing a cardiovascular event.

5. The method according to any one of claims 1 to 4, wherein the subject is a human.

6. The method of claim 5 , wherein the subject is a human after developing critical limb ischemia.

7. The method of claim 5 , wherein the subject is a chronic maintenance dialysis patient.

Citation Information

Patent Citations

  • Soluble cd40l (cd154) as a prognostic marker for atherosclerosis

    JP2005515407A

  • Inspection method of cardiovascular event onset risk

    JP2013228229A

  • Future cardiac event biomarkers

    WO2009034470A2